J Clin Oncol:患者报道结果测量信息系统(PROMIS)的性兴趣和满意度测量有效性研究

2019-09-06 AlexYang MedSci原创

根治性前列腺切除术后患者报道的结果聚焦在了阴茎勃起功能上。到目前为止,还没有研究去验证前列腺癌患者中患者报道结果测量信息系统(PROMIS)的性兴趣和满意度测量有效性情况,或者这些测量结果与勃起功能的相关性情况。另外,这些测量对治疗的临床响应情况数据也缺乏。最近,有研究人员验证和调查了这些测量在根治性前列腺切除后男性中的临床实用性情况。研究总共包括了1604名患者,时间为2014年5月到2016年

根治性前列腺切除术后患者报道的结果聚焦在了阴茎勃起功能上。到目前为止,还没有研究去验证前列腺癌患者中患者报道结果测量信息系统(PROMIS)的性兴趣和满意度测量有效性情况,或者这些测量结果与勃起功能的相关性情况。另外,这些测量对治疗的临床响应情况数据也缺乏。最近,有研究人员验证和调查了这些测量在根治性前列腺切除后男性中的临床实用性情况。

研究总共包括了1604名患者,时间为2014年5月到2016年1月,这些患者均经历了机器人根治性前列腺切除术。研究支持了PROMIS测量的收敛效度和区分效度。平均PROMIS性兴趣T评分从基线时间到第3个月显著减少(P=0.001),而从第3个月到第24个月显著增加,第24个月得分明显超过了基线得分(P<0.001)。平均的PROMIS满意度T得分从基线点到第3个月减少,而从第3个月到第24个月显著增加(P<0.02)。

最后,研究人员指出,PROMIS性生活和性兴趣的整体满意度测量在前列腺癌生存中是基础的测量。尽管功能受损,但患者对性还是很感兴趣且能挽回满足感。因此,他们的结果为根治性前列腺切除术后患者为中心的生存目标的性功能恢复方面提供了新的认识。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1865700, encodeId=9ab21865e00ab, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Oct 20 03:09:00 CST 2019, time=2019-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2020094, encodeId=a2862020094b7, content=<a href='/topic/show?id=9a7f14e277b' target=_blank style='color:#2F92EE;'>#PROM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14727, encryptionId=9a7f14e277b, topicName=PROM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Thu Jul 16 07:09:00 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478688, encodeId=71b814e86884a, content=<a href='/topic/show?id=d561665e7af' target=_blank style='color:#2F92EE;'>#满意度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66577, encryptionId=d561665e7af, topicName=满意度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1627448984, createdName=ms1692212821629096, createdTime=Sun Sep 08 12:09:00 CST 2019, time=2019-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602195, encodeId=de0e1602195b7, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sun Sep 08 12:09:00 CST 2019, time=2019-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1037900, encodeId=1db3103e900d6, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sat Sep 07 00:09:00 CST 2019, time=2019-09-07, status=1, ipAttribution=)]
    2019-10-20 minlingfeng
  2. [GetPortalCommentsPageByObjectIdResponse(id=1865700, encodeId=9ab21865e00ab, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Oct 20 03:09:00 CST 2019, time=2019-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2020094, encodeId=a2862020094b7, content=<a href='/topic/show?id=9a7f14e277b' target=_blank style='color:#2F92EE;'>#PROM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14727, encryptionId=9a7f14e277b, topicName=PROM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Thu Jul 16 07:09:00 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478688, encodeId=71b814e86884a, content=<a href='/topic/show?id=d561665e7af' target=_blank style='color:#2F92EE;'>#满意度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66577, encryptionId=d561665e7af, topicName=满意度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1627448984, createdName=ms1692212821629096, createdTime=Sun Sep 08 12:09:00 CST 2019, time=2019-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602195, encodeId=de0e1602195b7, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sun Sep 08 12:09:00 CST 2019, time=2019-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1037900, encodeId=1db3103e900d6, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sat Sep 07 00:09:00 CST 2019, time=2019-09-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1865700, encodeId=9ab21865e00ab, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Oct 20 03:09:00 CST 2019, time=2019-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2020094, encodeId=a2862020094b7, content=<a href='/topic/show?id=9a7f14e277b' target=_blank style='color:#2F92EE;'>#PROM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14727, encryptionId=9a7f14e277b, topicName=PROM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Thu Jul 16 07:09:00 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478688, encodeId=71b814e86884a, content=<a href='/topic/show?id=d561665e7af' target=_blank style='color:#2F92EE;'>#满意度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66577, encryptionId=d561665e7af, topicName=满意度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1627448984, createdName=ms1692212821629096, createdTime=Sun Sep 08 12:09:00 CST 2019, time=2019-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602195, encodeId=de0e1602195b7, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sun Sep 08 12:09:00 CST 2019, time=2019-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1037900, encodeId=1db3103e900d6, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sat Sep 07 00:09:00 CST 2019, time=2019-09-07, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1865700, encodeId=9ab21865e00ab, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Oct 20 03:09:00 CST 2019, time=2019-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2020094, encodeId=a2862020094b7, content=<a href='/topic/show?id=9a7f14e277b' target=_blank style='color:#2F92EE;'>#PROM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14727, encryptionId=9a7f14e277b, topicName=PROM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Thu Jul 16 07:09:00 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478688, encodeId=71b814e86884a, content=<a href='/topic/show?id=d561665e7af' target=_blank style='color:#2F92EE;'>#满意度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66577, encryptionId=d561665e7af, topicName=满意度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1627448984, createdName=ms1692212821629096, createdTime=Sun Sep 08 12:09:00 CST 2019, time=2019-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602195, encodeId=de0e1602195b7, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sun Sep 08 12:09:00 CST 2019, time=2019-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1037900, encodeId=1db3103e900d6, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sat Sep 07 00:09:00 CST 2019, time=2019-09-07, status=1, ipAttribution=)]
    2019-09-08 sunylz
  5. [GetPortalCommentsPageByObjectIdResponse(id=1865700, encodeId=9ab21865e00ab, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Oct 20 03:09:00 CST 2019, time=2019-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2020094, encodeId=a2862020094b7, content=<a href='/topic/show?id=9a7f14e277b' target=_blank style='color:#2F92EE;'>#PROM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14727, encryptionId=9a7f14e277b, topicName=PROM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Thu Jul 16 07:09:00 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478688, encodeId=71b814e86884a, content=<a href='/topic/show?id=d561665e7af' target=_blank style='color:#2F92EE;'>#满意度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66577, encryptionId=d561665e7af, topicName=满意度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1627448984, createdName=ms1692212821629096, createdTime=Sun Sep 08 12:09:00 CST 2019, time=2019-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602195, encodeId=de0e1602195b7, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sun Sep 08 12:09:00 CST 2019, time=2019-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1037900, encodeId=1db3103e900d6, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sat Sep 07 00:09:00 CST 2019, time=2019-09-07, status=1, ipAttribution=)]
    2019-09-07 anti-cancer

    谢谢梅斯分享这么多精彩信息

    0

相关资讯

盘点:前列腺相关研究进展

前列腺是男性生殖器附属腺中最大的实质性器官。由前列腺组织和肌组织构成。前列腺炎是指由多种复杂原因引起的,以尿道刺激症状和慢性盆腔疼痛为主要临床表现的前列腺疾病。前列腺炎是泌尿外科的常见病,在泌尿外科50岁以下男性患者中占首位。前列腺癌是指发生在前列腺的上皮性恶性肿瘤。2004年WHO《泌尿系统及男性生殖器官肿瘤病理学和遗传学》中前列腺癌病理类型上包括腺癌(腺泡腺癌)、导管腺癌、尿路上皮癌、鳞状

Sci Rep:标准临床3T前列腺MRI在盆腔淋巴结分期中的准确度研究

最近,有研究人员在前列腺癌(PCa)中评估了前列腺3TMRI在盆腔淋巴结(LN)分期中的表现情况,并将68镓-前列腺特异性膜抗原PET-CT(68Ga-PSMAPET-CT)作为LN检测的参考标准。研究共包括了130名PCa患者,他们在180内经历了非对比度增强多参数前列腺3TMRI和68Ga-PSMA-PET-CT。研究发现,由68Ga-PSMAPET-CT检测到的187个LN转移(n=43名患

J Cell Biochem:MicroRNA-140能够通过靶向YES原癌基因1来抑制前列腺癌细胞的侵入和迁移

前列腺癌(PCa)是男性泌尿生殖系统的一种具有侵略性的恶性肿瘤。最近,有研究人员确定了microRNA-140(miR-140)对PCa的影响。研究人员将miR-140或者阴性对照转染到了PCa细胞中,并使用MTT、伤口愈合试验和Transwell试验确定了miR-140在细胞增殖、迁移和浸润中的作用情况。研究人员还利用双荧光素酶报告试验确认了miR-140与YES原癌基因之间的关系。研究发现,m

Eur Urol:前列腺癌主动监测期间活检结果的预测研究

主动监测(AS)前列腺癌(PCa)男性均要进行常规前列腺活检,该活检给患者带来负担且经常是没有必要的干预,还存在风险。对低风险疾病的男性进行再分类也许能够减少活检的次数。最近,有研究人员评估了两个PASS-RCs的外部有效性,该工具在监测活检中对再分类可能性进行评估,使用上次活检后几个月的数据、年龄、身体质量指数、前列腺特异性抗原、前列腺体积、先前阴性活检数和上次活检阳性病灶的比例。研究包括了5个

Prostate Cancer P D:术前PI-RADS V2评分能够提高临床列线图的准确性

淋巴结浸润(LNI)是前列腺癌(PCa)的一种强烈的不良预后因素。最近, 有研究人员评估了前列腺成像报告和数据系统V2(PI-RADS V2)评分在评估LN转移中的作用。同时,研究人员还调查了当于临床列线图组合运用来对PCa患者的LNI进行预测时,PI-RADS V2评分的其他用途。研究人员回顾性的鉴定了308名经历了多参数核磁共振成像(mpMRI)和RP且进行了盆腔淋巴结清扫(PLND)的患者,

Eur Urol Oncol:根治性前列腺癌切除术后抑郁风险研究

前列腺癌患者抑郁的发展依赖于多个疾病相关和患者相关的因素。最近,有研究人员调查了根治性前列腺癌切除术后抑郁的风险情况,并且主要关注手术和随后的挽救性放射疗法或者雄激素阻断疗法治疗的影响。在跟踪调查的18年中,研究发现抑郁的累积患病率在那些经历手术的男性中要比无癌症男性高,尤其是在那些经历了雄激素阻断治疗的男性中。在调整了年龄、手术年数、收入和同居情况后,研究人员发现,与没有随后的治疗相比,随后雄激